Literature DB >> 15049931

Effects of glycaemic control on cardiovascular disease in diabetic American Indians: the Strong Heart Study.

W Q Lu1, H E Resnick, K A Jablonski, A K Jain, K L Jones, D C Robbins, B V Howard.   

Abstract

AIMS: Diabetes increases the risk of cardiovascular disease (CVD). Only part of this excess risk is explained by diabetes-associated hypertension, obesity, and lipid disorders. Poor glycaemic control may help explain the residual CVD risk. The aim of this study was to determine whether variations in glycaemic control are associated with CVD risk in diabetic individuals.
METHODS: We examined longitudinal data from the Strong Heart Study, a population-based study of CVD and its risk factors among American Indians (a population with a high prevalence of diabetes). Diabetes was defined using the 1998 World Health Organization criteria: fasting plasma glucose >/= 126 mg/dl or 2-h plasma glucose >/= 200 mg/dl. American Diabetes Association guidelines for glycaemic control were used: good, A(1c) < 7%; fair, 7-7.9%; and poor, >/= 8%. The analysis was based on data from diabetic individuals with no CVD at baseline.
RESULTS: During 9 years of follow-up, 494 of the 2011 diabetic participants developed CVD. Although Cox multivariate regression modelling showed dose-response effects of glycaemic control on overall CVD and coronary heart disease (CHD) incidence, the relationships were weakened when adjusted for confounding variables. Kaplan-Meier analysis, however, showed that diabetic individuals with poor baseline glycaemic control had significantly increased proportions of overall CVD and CHD (P = 0.001) during the 9 years of follow-up, compared with those who had good or fair control.
CONCLUSIONS: These findings highlight the importance of risk factors, such as high blood pressure and dyslipidaemia, in increasing CVD risk in those with diabetes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15049931     DOI: 10.1111/j.1464-5491.2004.01137.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  6 in total

1.  Prognostic value of multiple biomarkers in American Indians free of clinically overt cardiovascular disease (from the Strong Heart Study).

Authors:  Jorge R Kizer; Daniel G Krauser; Richard J Rodeheffer; John C Burnett; Peter M Okin; Mary J Roman; Jason G Umans; Lyle G Best; Elisa T Lee; Richard B Devereux
Journal:  Am J Cardiol       Date:  2009-06-03       Impact factor: 2.778

2.  Predictors of all-cause and cardiovascular-specific mortality in type 2 diabetes: A competing risk modeling of an Iranian population.

Authors:  Sahar Sadeghpour; Elham Faghihimani; Akbar Hassanzadeh; Masoud Amini; Marjan Mansourian
Journal:  Adv Biomed Res       Date:  2016-05-11

3.  Integrating community health representatives with health care systems: clinical outcomes among individuals with diabetes in Navajo Nation.

Authors:  Letizia Trevisi; John E Orav; Sidney Atwood; Christian Brown; Cameron Curley; Caroline King; Olivia Muskett; Hannah Sehn; Katrina A Nelson; Mae-Gilene Begay; Sonya S Shin
Journal:  Int J Equity Health       Date:  2019-11-27

4.  Lipoprotein-associated phospholipase A(2) mass and activity and risk of cardiovascular disease in a population with high prevalences of obesity and diabetes: the Strong Heart Study.

Authors:  Jorge R Kizer; Jason G Umans; Jianhui Zhu; Richard B Devereux; Robert L Wolfert; Elisa T Lee; Barbara V Howard
Journal:  Diabetes Care       Date:  2012-02-14       Impact factor: 19.112

5.  Association of diabetes and cancer mortality in American Indians: the Strong Heart Study.

Authors:  Lyle G Best; Esther García-Esquinas; Jeun-Liang Yeh; Fawn Yeh; Ying Zhang; Elisa T Lee; Barbara V Howard; John H Farley; Thomas K Welty; Dorothy A Rhoades; Everett R Rhoades; Jason G Umans; Ana Navas-Acien
Journal:  Cancer Causes Control       Date:  2015-08-07       Impact factor: 2.506

6.  Cause-Specific Risk Factors of Death in Individuals with Diabetes: A Competing Risks Modeling.

Authors:  Marjan Mansourian; Sahar Sadeghpour; Ashraf Aminorroaya; Masoud Amini; Tohid Jafari-Koshki
Journal:  Int J Endocrinol Metab       Date:  2019-06-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.